1. Volume 72, Issue 5, Pages 738-744 (November 2017)
Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer 
Skyler B. Johnson, Nataniel H. Lester-Coll, Jacqueline R. Kelly, Benjamin H. Kann, James B. Yu, Sameer K. Nath 
European Urology 
Volume 72, Issue 5, Pages (November 2017)
DOI: /j.eururo
Copyright © 2017 European Association of Urology Terms and Conditions

2. Fig. 1
Proportion of patients treated with androgen suppression and external-beam radiation with low-dose rate brachytherapy (LDR-B) boost between 2004 and 2012 relative to dose-escalated external beam radiation therapy alone.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions

3. Fig. 2
(A) Unadjusted and (B) propensity-matched Kaplan-Meier survival curves by either dose-escalated external beam radiation therapy (DE-EBRT) or low-dose-rate brachytherapy (LDR-B) boost.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions

4. Fig. 3
Kaplan-Meier survival curves for men aged <60 yr with no comorbidities and stratified by treatment type with either dose-escalated external beam radiation therapy (DE-EBRT) or low-dose-rate brachytherapy (LDR-B) boost (7-yr overall survival 85% vs 90%; p<0.001).
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions